Transmitted from the infected mosquitoes, Chikungunya is a viral disease causing severe pains in the joints along with fever. This viral disease also shares some of the most common clinical signs as seen in dengue. Indeed, there is a greater possibility that this viral disease could be misdiagnosed in the places where dengue is widespread. Occurring in parts of Asia, America, Africa and some other subcontinents, this viral disease is increasing vastly.
Therefore, Zydus Cadila, the drug firm is announced to go with Takeda Pharmaceutical Company Ltd of Japan, for a partnership for discovering and developing a proper vaccine for chikungunya. Currently, no vaccine is discovered to cure this type of viral disease. Hence, this agreement is a broad-based kind and will include developing the vaccine starting from its early stage to the final commercialization.
The managing director and chairman of Cadila Healthcare, MD Pankaj R Patel said that by joining hands with Takeda, the Zydus team is taking an important step in the field of preventing burden for diseases. According to him, this is an initial step and an important research which would be beneficial for their developmental potentials.
On the other hand, Takeda is a renowned global pharmaceutical company. In the field of global health activities, Takeda is the centre that develops important vaccines for infectious diseases. The chief operating officer and a vaccine leader, Rahul Singhvi said that the step that has been taken by the team of Takeda is a major step in the field of giving health based commitment not only in the developing countries but also “elsewhere” around the globe.